Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
National Institutes for Pharmaceutical Education and Research (NIPERs) and Pharma Industries signed 17 MoU to bridge gap betwwen academic education and industrial needs. One of the critical factors in building innovation ecosystem and for Drug Discovery is Academia-Industry linkage. Department of Pharmaceuticals (DoP) for the last one year has actively engaged both the NIPERs and the Pharma Industry to build partnership in areas of education, research and development.
Widely thought to be essential for good health, Omega 3 fatty acid supplements may not be of much help in treating major depressive disorders, suggests new research.
(Business Wire India); Piramal Enterprises’ Consumer Products Division announces the acquisition of the baby-care brand “Little’s”, which includes the entire product range across six categories.
Premature ejaculation including female sexual dysfunction should not be classified as an illness, argue researchers, adding that the illness factor may have been constructed by sexual medicine experts under the influence of drug companies.
Once they enter memory, depressive thoughts can linger for long in affected people, and this extended duration may reduce the amount of information that these individuals can remember, suggests new research.
[adsense:336x280:8701650588]
Like HIV and Ebola, the hepatitis A virus is of likely animal origin, finds a large-scale study looking into the evolutionary origins of the global pathogen.
Particulate matter and nitric dioxide emissions from industrial plants or vehicles increase the risk of heart attacks, despite being within 'safe' levels of air pollution, a new study has claimed. The study examined the effect of short term exposure to air pollution on the risk of ST-segment elevation myocardial infarction (STEMI). This type of myocardial infarction (heart attack) has the worst prognosis and is caused by thrombotic occlusion of a coronary artery that damages the heart.
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations of cabotegravir (ViiV Healthcare) and rilpivirine (Janssen) were comparable in maintaining viral suppression rates to a three drug oral regimen of investigational cabotegravir and two nucleoside reverse transcriptase inhibitors (NRTIs). The 32 week results of LATTE 2 will be presented at a forthcoming scientific conference. ViiV Healthcare and Janssen Sciences Ireland UC (Janssen) are collaborating to conduct LATTE 2.
Merck Serono has signed a collaboration with Polish biotechnology firm Selvita to jointly discover small molecule based drugs targeting proteins involved in cancer cell metabolism.
GSK and Merck, known as MSD outside the US and Canada, announced the initiation of a phase I clinical trial designed to evaluate GSK’s investigational immunotherapy GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda® (pembrolizumab) in patients with locally advanced, recurrent or metastatic solid tumour(s) that have progressed after standard treatment.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
